{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:42:58Z","timestamp":1792809778869,"version":"4.5.0"},"reference-count":195,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"NIH\/NIAID","award":["AI127823"],"award-info":[{"award-number":["AI127823"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.coviro.2018.12.009","type":"journal-article","created":{"date-parts":[[2019,2,10]],"date-time":"2019-02-10T19:45:43Z","timestamp":1549827943000},"page":"1-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Status of antiviral therapeutics against rabies virus and related emerging lyssaviruses"],"prefix":"10.1016","volume":"35","author":[{"given":"Venice","family":"Du Pont","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard K","family":"Plemper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias J","family":"Schnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2018.12.009_bib0005","first-page":"15","article-title":"Chapter 2: mesopotamia","volume":"95","author":"Fales","year":"2010","journal-title":"Handb Clin Neurol"},{"issue":"93","key":"10.1016\/j.coviro.2018.12.009_bib0010","first-page":"201","article-title":"The WHO position on rabies immunization - 2018 updates","volume":"16","author":"O\u2019Brien","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2018.12.009_bib0015","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/13550280601178226","article-title":"Proteomic profiling reveals that rabies virus infection results in differential expression of host proteins involved in ion homeostasis and synaptic physiology in the central nervous system","volume":"13","author":"Dhingra","year":"2007","journal-title":"J Neurovirol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0020","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/00005072-198611000-00002","article-title":"Axonal transport of rabies virus in the central nervous system of the rat","volume":"45","author":"Gillet","year":"1986","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0025","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s13365-015-0351-1","article-title":"Diabolical effects of rabies encephalitis","volume":"22","author":"Jackson","year":"2016","journal-title":"J Neurovirol"},{"key":"10.1016\/j.coviro.2018.12.009_sbref0030","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1146\/annurev-virology-100114-055157","article-title":"Everything you always wanted to know about rabies virus (but were afraid to ask)","volume":"2","author":"Davis","year":"2015","journal-title":"Annu Rev Virol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0035","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/B978-0-12-387040-7.00003-2","article-title":"Evasive strategies in rabies virus infection","volume":"79","author":"Lafon","year":"2011","journal-title":"Adv Virus Res"},{"key":"10.1016\/j.coviro.2018.12.009_bib0040","doi-asserted-by":"crossref","DOI":"10.3390\/v8080231","article-title":"Subversion of the immune response by rabies virus","volume":"8","author":"Scott","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2018.12.009_sbref0045","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1292\/jvms.16-0092","article-title":"The importance of immune evasion in the pathogenesis of rabies virus","volume":"78","author":"Ito","year":"2016","journal-title":"J Vet Med Sci"},{"key":"10.1016\/j.coviro.2018.12.009_bib0050","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/inthealth\/ihu071","article-title":"Human rabies deaths in Africa: breaking the cycle of indifference","volume":"7","author":"Dodet","year":"2015","journal-title":"Int Health"},{"key":"10.1016\/j.coviro.2018.12.009_bib0055","first-page":"425","article-title":"WHO position paper","volume":"82","author":"Rabies vaccines","year":"2007","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.coviro.2018.12.009_bib0060","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1128\/JVI.75.7.3268-3276.2001","article-title":"Evidence of two Lyssavirus phylogroups with distinct pathogenicity and immunogenicity","volume":"75","author":"Badrane","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0065","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0378-1135(90)90141-H","article-title":"From rabies to rabies-related viruses","volume":"23","author":"Bourhy","year":"1990","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0070","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1128\/jcm.26.12.2489-2494.1988","article-title":"Monoclonal antibodies to Mokola virus for identification of rabies and rabies-related viruses","volume":"26","author":"Bussereau","year":"1988","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0075","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0769-2617(88)80014-5","article-title":"Immunological relationships between rabies virus and rabies-related viruses studied with monoclonal antibodies to Mokola virus","volume":"139","author":"Vincent","year":"1988","journal-title":"Ann Inst Pasteur Virol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0080","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1080\/13550280590900427","article-title":"Rabies virus receptors","volume":"11","author":"Lafon","year":"2005","journal-title":"J Neurovirol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0085","article-title":"Pathogenicity and immunogenicity of recombinant rabies viruses expressing the Lagos bat virus matrix and glycoprotein: perspectives for a pan-lyssavirus vaccine","volume":"2","author":"Kgaladi","year":"2017","journal-title":"Trop Med Infect Dis"},{"key":"10.1016\/j.coviro.2018.12.009_bib0090","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1099\/vir.0.048827-0","article-title":"Interspecies protein substitution to investigate the role of the lyssavirus glycoprotein","volume":"94","author":"Marston","year":"2013","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0095","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jmb.2009.09.042","article-title":"Binding of rabies virus polymerase cofactor to recombinant circular nucleoprotein-RNA complexes","volume":"394","author":"Ribeiro Ede","year":"2009","journal-title":"J Mol Biol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0100","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/1348-0421.12058","article-title":"Importance of rabies virus nucleoprotein in viral evasion of interferon response in the brain","volume":"57","author":"Masatani","year":"2013","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0105","doi-asserted-by":"crossref","first-page":"8226","DOI":"10.1128\/JVI.00809-16","article-title":"Roles of the rabies virus phosphoprotein isoforms in pathogenesis","volume":"90","author":"Okada","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.12.009_sbref0110","article-title":"Evaluation of in vitro inhibitory potential of type-I interferons and different antiviral compounds on rabies virus replication","author":"Marosi","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2018.12.009_bib0115","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1128\/JVI.80.6.2675-2683.2006","article-title":"Inhibition of interferon signaling by rabies virus phosphoprotein P: activation-dependent binding of STAT1 and STAT2","volume":"80","author":"Brzozka","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0120","doi-asserted-by":"crossref","first-page":"7673","DOI":"10.1128\/JVI.79.12.7673-7681.2005","article-title":"Identification of the rabies virus alpha\/beta interferon antagonist: phosphoprotein P interferes with phosphorylation of interferon regulatory factor 3","volume":"79","author":"Brzozka","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0125","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1099\/0022-1317-71-5-1153","article-title":"Sequence comparison of five polymerases (L proteins) of unsegmented negative-strand RNA viruses: theoretical assignment of functional domains","volume":"71","author":"Poch","year":"1990","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0130","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/01652176.2017.1343516","article-title":"Rabies - epidemiology, pathogenesis, public health concerns and advances in diagnosis and control: a comprehensive review","volume":"37","author":"Singh","year":"2017","journal-title":"Vet Q"},{"key":"10.1016\/j.coviro.2018.12.009_bib0135","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1006\/viro.1995.0063","article-title":"Polymerase activity of in vitro mutated rabies virus L protein","volume":"214","author":"Schnell","year":"1995","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2018.12.009_bib0140","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1128\/jvi.67.3.1334-1339.1993","article-title":"Transcriptional activity and mutational analysis of recombinant vesicular stomatitis virus RNA polymerase","volume":"67","author":"Sleat","year":"1993","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0145","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02322-16","article-title":"5\u2032-Phospho-RNA acceptor specificity of GDP polyribonucleotidyltransferase of vesicular stomatitis virus in mRNA capping","volume":"91","author":"Ogino","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0150","doi-asserted-by":"crossref","DOI":"10.3390\/v8050144","article-title":"The rabies virus L protein catalyzes mRNA capping with GDP polyribonucleotidyltransferase activity","volume":"8","author":"Ogino","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2018.12.009_bib0155","doi-asserted-by":"crossref","first-page":"11499","DOI":"10.1128\/JVI.01057-07","article-title":"Vesicular stomatitis virus mRNA capping machinery requires specific cis-acting signals in the RNA","volume":"81","author":"Wang","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0160","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.molcel.2006.11.013","article-title":"Unconventional mechanism of mRNA capping by the RNA-dependent RNA polymerase of vesicular stomatitis virus","volume":"25","author":"Ogino","year":"2007","journal-title":"Mol Cell"},{"key":"10.1016\/j.coviro.2018.12.009_bib0165","doi-asserted-by":"crossref","first-page":"8493","DOI":"10.1073\/pnas.0509821103","article-title":"A unique strategy for mRNA cap methylation used by vesicular stomatitis virus","volume":"103","author":"Li","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2018.12.009_bib0170","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1128\/JVI.03420-13","article-title":"mRNA cap methylation influences pathogenesis of vesicular stomatitis virus in vivo","volume":"88","author":"Ma","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0175","doi-asserted-by":"crossref","first-page":"11043","DOI":"10.1128\/JVI.01426-09","article-title":"Ribose 2\u2032-O methylation of the vesicular stomatitis virus mRNA cap precedes and facilitates subsequent guanine-N-7 methylation by the large polymerase protein","volume":"83","author":"Rahmeh","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0180","doi-asserted-by":"crossref","first-page":"13373","DOI":"10.1128\/JVI.79.21.13373-13384.2005","article-title":"Amino acid residues within conserved domain VI of the vesicular stomatitis virus large polymerase protein essential for mRNA cap methyltransferase activity","volume":"79","author":"Li","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0185","doi-asserted-by":"crossref","first-page":"17091","DOI":"10.1038\/nrdp.2017.91","article-title":"Rabies","volume":"3","author":"Fooks","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.coviro.2018.12.009_bib0190","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1056\/NEJMoa050382","article-title":"Survival after treatment of rabies with induction of coma","volume":"352","author":"Willoughby","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2018.12.009_bib0195","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/cid\/cir483","article-title":"Failure of the Milwaukee protocol in a child with rabies","volume":"53","author":"Aramburo","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coviro.2018.12.009_bib0200","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1080\/00365540902798333","article-title":"Applying the Milwaukee protocol to treat canine rabies in equatorial guinea","volume":"41","author":"Rubin","year":"2009","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.coviro.2018.12.009_bib0205","first-page":"33","article-title":"Treatment of rabies in mice and foxes with antiviral compounds","volume":"32","author":"Bussereau","year":"1988","journal-title":"Acta Virol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0210","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.antiviral.2013.01.003","article-title":"Current and future approaches to the therapy of human rabies","volume":"99","author":"Jackson","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2018.12.009_bib0215","doi-asserted-by":"crossref","first-page":"24591","DOI":"10.1016\/S0021-9258(19)74507-4","article-title":"Eicar (5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide). A novel potent inhibitor of inosinate dehydrogenase activity and guanylate biosynthesis","volume":"268","author":"Balzarini","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2018.12.009_bib0220","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1128\/AAC.01795-13","article-title":"Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon","volume":"58","author":"Debing","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2018.12.009_bib0225","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1128\/JVI.79.3.1943-1947.2005","article-title":"The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase","volume":"79","author":"Leyssen","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0230","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/bmj.299.6703.830","article-title":"Failure of interferon alfa and tribavirin in rabies encephalitis","volume":"299","author":"Warrell","year":"1989","journal-title":"BMJ"},{"key":"10.1016\/j.coviro.2018.12.009_bib0235","first-page":"443","article-title":"Rabies in China: recommendations for control","volume":"70","author":"Kureishi","year":"1992","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.coviro.2018.12.009_bib0240","first-page":"469","article-title":"Human rabies\u2014Texas","volume":"33","author":"Centers for Disease Control","year":"1984","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.coviro.2018.12.009_bib0245","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1128\/AAC.22.1.108","article-title":"Selective inhibition of functional lymphocyte subpopulations by ribavirin","volume":"22","author":"Powers","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2018.12.009_bib0250","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1093\/infdis\/jit829","article-title":"Interaction of rabies virus P-protein with STAT proteins is critical to lethal rabies disease","volume":"209","author":"Wiltzer","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2018.12.009_bib0255","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.virol.2005.02.005","article-title":"Nucleocytoplasmic shuttling of the rabies virus P protein requires a nuclear localization signal and a CRM1-dependent nuclear export signal","volume":"334","author":"Pasdeloup","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2018.12.009_bib0260","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1242\/jcs.045542","article-title":"Dual modes of rabies P-protein association with microtubules: a novel strategy to suppress the antiviral response","volume":"122","author":"Moseley","year":"2009","journal-title":"J Cell Sci"},{"key":"10.1016\/j.coviro.2018.12.009_bib0265","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1128\/JVI.01930-06","article-title":"The nucleocytoplasmic rabies virus P protein counteracts interferon signaling by inhibiting both nuclear accumulation and DNA binding of STAT1","volume":"81","author":"Vidy","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0270","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.vetmic.2006.03.019","article-title":"Evaluation of antiviral activity of phenolic compounds and derivatives against rabies virus","volume":"116","author":"Chavez","year":"2006","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0275","doi-asserted-by":"crossref","first-page":"E861","DOI":"10.1073\/pnas.1210198110","article-title":"Host-rabies virus protein-protein interactions as druggable antiviral targets","volume":"110","author":"Lingappa","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2018.12.009_bib0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2018.10.016","article-title":"Pyrimethamine inhibits rabies virus replication in vitro","volume":"161","author":"Rogee","year":"2018","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2018.12.009_bib0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2018.03.011","article-title":"Ribavirin-related compounds exert in vitro inhibitory effects toward rabies virus","volume":"154","author":"Anindita","year":"2018","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2018.12.009_bib0290","article-title":"Dermaseptins as potential antirabies compounds","author":"Mechlia","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2018.12.009_bib0295","doi-asserted-by":"crossref","DOI":"10.3390\/v8110279","article-title":"Rabies control and treatment: from prophylaxis to strategies with curative potential","volume":"8","author":"Zhu","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2018.12.009_sbref0300","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/infdis\/jiv586","article-title":"Efficacy of favipiravir (T-705) in rabies postexposure prophylaxis","volume":"213","author":"Yamada","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2018.12.009_bib0305","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.virusres.2012.07.024","article-title":"Small interfering RNAs targeting the rabies virus nucleoprotein gene","volume":"169","author":"Yang","year":"2012","journal-title":"Virus Res"},{"key":"10.1016\/j.coviro.2018.12.009_bib0310","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2174\/187152611795768079","article-title":"Human rabies encephalitis prevention and treatment: progress since Pasteur\u2019s discovery","volume":"11","author":"Dacheux","year":"2011","journal-title":"Infect Disord Drug Targets"},{"key":"10.1016\/j.coviro.2018.12.009_sbref0315","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.2174\/0929867324666170815102917","article-title":"Structure properties and mechanisms of action of naturally originated phenolic acids and their derivatives against human viral infections","volume":"24","author":"Wu","year":"2017","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.coviro.2018.12.009_bib0320","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1002\/j.1460-2075.1994.tb06739.x","article-title":"Infectious rabies viruses from cloned cDNA","volume":"13","author":"Schnell","year":"1994","journal-title":"EMBO J"},{"key":"10.1016\/j.coviro.2018.12.009_bib0325","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1128\/jvi.68.2.713-719.1994","article-title":"Rescue of synthetic genomic RNA analogs of rabies virus by plasmid-encoded proteins","volume":"68","author":"Conzelmann","year":"1994","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0330","first-page":"335","article-title":"Assessment the efficiency of the constructed minigenome of rabies virus using PV strain as helper virus","volume":"19","author":"Ajorloo","year":"2016","journal-title":"Arch Iran Med"},{"key":"10.1016\/j.coviro.2018.12.009_bib0335","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.virusres.2015.05.023","article-title":"G gene-deficient single-round rabies viruses for neuronal circuit analysis","volume":"216","author":"Ghanem","year":"2016","journal-title":"Virus Res"},{"key":"10.1016\/j.coviro.2018.12.009_bib0340","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1086\/605949","article-title":"Replication-deficient rabies virus-based vaccines are safe and immunogenic in mice and nonhuman primates","volume":"200","author":"Cenna","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2018.12.009_bib0345","doi-asserted-by":"crossref","first-page":"6405","DOI":"10.1016\/j.vaccine.2008.08.069","article-title":"Immune modulating effect by a phosphoprotein-deleted rabies virus vaccine vector expressing two copies of the rabies virus glycoprotein gene","volume":"26","author":"Cenna","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2018.12.009_bib0350","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1348-0421.2005.tb03692.x","article-title":"Characterization of M gene-deficient rabies virus with advantages of effective immunization and safety as a vaccine strain","volume":"49","author":"Ito","year":"2005","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0355","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.virusres.2005.03.011","article-title":"Characterization of P gene-deficient rabies virus: propagation, pathogenicity and antigenicity","volume":"111","author":"Morimoto","year":"2005","journal-title":"Virus Res"},{"key":"10.1016\/j.coviro.2018.12.009_bib0360","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.virol.2003.10.001","article-title":"Generation and characterization of P gene-deficient rabies virus","volume":"318","author":"Shoji","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2018.12.009_bib0365","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1128\/JVI.76.4.2024-2027.2002","article-title":"A novel expression cassette of lyssavirus shows that the distantly related Mokola virus can rescue a defective rabies virus genome","volume":"76","author":"Le Mercier","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0370","first-page":"1","article-title":"Toward the development of a single-round infection assay based on EGFP reporting for anti-HIV-1 drug discovery","volume":"4","author":"Soezi","year":"2015","journal-title":"Rep Biochem Mol Biol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0375","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042609","article-title":"High-throughput screening and rapid inhibitor triage using an infectious chimeric Hepatitis C virus","volume":"7","author":"Wichroski","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2018.12.009_bib0380","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.virusres.2015.07.013","article-title":"Development and applications of single-cycle infectious influenza A virus (sciIAV)","volume":"216","author":"Nogales","year":"2016","journal-title":"Virus Res"},{"key":"10.1016\/j.coviro.2018.12.009_bib0385","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.antiviral.2017.08.005","article-title":"An RNA polymerase II-driven Ebola virus minigenome system as an advanced tool for antiviral drug screening","volume":"146","author":"Nelson","year":"2017","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2018.12.009_bib0390","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/978-1-4939-7116-9_6","article-title":"Modeling Ebola virus genome replication and transcription with minigenome systems","volume":"1628","author":"Cressey","year":"2017","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0395","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/978-1-4939-6964-7_11","article-title":"Reverse genetics systems for filoviruses","volume":"1602","author":"Hoenen","year":"2017","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.coviro.2018.12.009_sbref0400","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1089\/omi.2015.0137","article-title":"Pathway analysis of proteomics profiles in rabies infection: towards future biomarkers?","volume":"20","author":"Mehta","year":"2016","journal-title":"OMICS"},{"key":"10.1016\/j.coviro.2018.12.009_bib0405","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/omi.2014.0127","article-title":"Postgenomics biomarkers for rabies-the next decade of proteomics","volume":"19","author":"Mehta","year":"2015","journal-title":"OMICS"},{"key":"10.1016\/j.coviro.2018.12.009_bib0410","first-page":"77","article-title":"Discovery of a new drug\u2013from target identification to ultra-high-throughput screening","volume":"53","author":"Golz","year":"2007","journal-title":"Clin Lab"},{"key":"10.1016\/j.coviro.2018.12.009_bib0415","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1023\/A:1013824317218","article-title":"Combinatorial chemistry and high-throughput screening in drug discovery: different strategies and formats","volume":"5","author":"Seneci","year":"2000","journal-title":"Mol Divers"},{"key":"10.1016\/j.coviro.2018.12.009_bib0420","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020069","article-title":"Potent host-directed small-molecule inhibitors of myxovirus RNA-dependent RNA-polymerases","volume":"6","author":"Krumm","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coviro.2018.12.009_bib0425","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/978-3-642-61105-6_17","article-title":"Biotransformation and renal processing of nephrotoxic agents","volume":"18","author":"Dekant","year":"1996","journal-title":"Arch Toxicol Suppl"},{"key":"10.1016\/j.coviro.2018.12.009_bib0430","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1006\/taap.2000.9055","article-title":"The species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in rats","volume":"169","author":"Mutlib","year":"2000","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.coviro.2018.12.009_sbref0435","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007038","article-title":"Biology must develop herd immunity against bad-actor molecules","volume":"14","author":"Plemper","year":"2018","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2018.12.009_bib0440","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nm.2341","article-title":"EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy","volume":"17","author":"Lupberger","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2018.12.009_bib0445","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1159\/000360830","article-title":"The HCV life cycle: in vitro tissue culture systems and therapeutic targets","volume":"32","author":"Gerold","year":"2014","journal-title":"Dig Dis"},{"key":"10.1016\/j.coviro.2018.12.009_bib0450","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1586\/era.11.74","article-title":"Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer","volume":"11","author":"Hotta","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.coviro.2018.12.009_bib0455","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.3748\/wjg.14.5098","article-title":"Serious drug-induced liver disease secondary to ezetimibe","volume":"14","author":"Castellote","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0460","first-page":"734","article-title":"Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib","volume":"9","author":"Erba","year":"2011","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.coviro.2018.12.009_sbref0465","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd.2017.162","article-title":"Host-directed therapies for bacterial and viral infections","volume":"17","author":"Kaufmann","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.coviro.2018.12.009_bib0470","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1016\/S1473-3099(16)00078-5","article-title":"Host-directed therapies for infectious diseases: current status, recent progress, and future prospects","volume":"16","author":"Zumla","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coviro.2018.12.009_bib0475","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1743-422X-11-40","article-title":"Host cell virus entry mediated by Australian bat lyssavirus G envelope glycoprotein occurs through a clathrin-mediated endocytic pathway that requires actin and Rab5","volume":"11","author":"Weir","year":"2014","journal-title":"Virol J"},{"key":"10.1016\/j.coviro.2018.12.009_bib0480","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005753","article-title":"Rabies internalizes into primary peripheral neurons via clathrin coated pits and requires fusion at the cell body","volume":"12","author":"Piccinotti","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2018.12.009_bib0485","doi-asserted-by":"crossref","first-page":"11637","DOI":"10.1128\/JVI.01648-13","article-title":"Uptake of rabies virus into epithelial cells by clathrin-mediated endocytosis depends upon actin","volume":"87","author":"Piccinotti","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0490","doi-asserted-by":"crossref","first-page":"6673","DOI":"10.1128\/JVI.00636-15","article-title":"Dynasore disrupts trafficking of herpes simplex virus proteins","volume":"89","author":"Mues","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0495","doi-asserted-by":"crossref","DOI":"10.3390\/v10030119","article-title":"Antiviral effects of ABMA against herpes simplex virus type 2 in vitro and in vivo","volume":"10","author":"Dai","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2018.12.009_bib0500","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1248\/yakushi.127.27","article-title":"Role of lipid rafts in trimeric G protein-mediated signal transduction","volume":"127","author":"Ohkubo","year":"2007","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.coviro.2018.12.009_bib0505","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1523\/JNEUROSCI.21-02-00504.2001","article-title":"Membrane lipid rafts are necessary for the maintenance of the (alpha)7 nicotinic acetylcholine receptor in somatic spines of ciliary neurons","volume":"21","author":"Bruses","year":"2001","journal-title":"J Neurosci"},{"key":"10.1016\/j.coviro.2018.12.009_bib0510","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/cne.10856","article-title":"Large clusters of alpha7-containing nicotinic acetylcholine receptors on chick spinal cord neurons","volume":"465","author":"Roth","year":"2003","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0515","doi-asserted-by":"crossref","first-page":"10922","DOI":"10.1074\/jbc.272.16.10922","article-title":"Association of p75(NTR) with caveolin and localization of neurotrophin-induced sphingomyelin hydrolysis to caveolae","volume":"272","author":"Bilderback","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2018.12.009_bib0520","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1016\/S0028-3908(00)00132-5","article-title":"Cluster formation of alpha7-containing nicotinic receptors at interneuronal interfaces in cell culture","volume":"39","author":"Conroy","year":"2000","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.coviro.2018.12.009_bib0525","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1099\/vir.0.81063-0","article-title":"Stable trimerization of recombinant rabies virus glycoprotein ectodomain is required for interaction with the p75NTR receptor","volume":"86","author":"Sissoeff","year":"2005","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0530","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1523\/JNEUROSCI.20-11-04021.2000","article-title":"Cytoskeletal links of neuronal acetylcholine receptors containing alpha 7 subunits","volume":"20","author":"Shoop","year":"2000","journal-title":"J Neurosci"},{"key":"10.1016\/j.coviro.2018.12.009_bib0535","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.virusres.2008.10.009","article-title":"Effect of cellular cholesterol depletion on rabies virus infection","volume":"139","author":"Hotta","year":"2009","journal-title":"Virus Res"},{"key":"10.1016\/j.coviro.2018.12.009_bib0540","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.micpath.2017.09.044","article-title":"Inhibition of MEK-ERK1\/2-MAP kinase signalling pathway reduces rabies virus induced pathologies in mouse model","volume":"112","author":"Manjunatha","year":"2017","journal-title":"Microb Pathog"},{"key":"10.1016\/j.coviro.2018.12.009_bib0545","first-page":"232","article-title":"Novel therapies in advanced renal cell carcinoma: management of adverse events from sorafenib and sunitinib","volume":"105","author":"Ivanyi","year":"2008","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.coviro.2018.12.009_bib0550","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1136\/gut.2009.182212","article-title":"New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication","volume":"58","author":"Himmelsbach","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.coviro.2018.12.009_bib0555","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.antiviral.2018.07.005","article-title":"Repurposed FDA-approved drug sorafenib reduces replication of Venezuelan equine encephalitis virus and other alphaviruses","volume":"157","author":"Lundberg","year":"2018","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2018.12.009_bib0560","article-title":"Combination therapy of rabies-infected mice with inhibitors of pro-inflammatory host response, antiviral compounds and human rabies immunoglobulin","author":"Marosi","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2018.12.009_bib0565","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.antiviral.2015.03.012","article-title":"The kinase-inhibitor sorafenib inhibits multiple steps of the Hepatitis C virus infectious cycle in vitro","volume":"118","author":"Descamps","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2018.12.009_bib0570","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.antiviral.2014.03.009","article-title":"The multi-targeted kinase inhibitor sorafenib inhibits enterovirus 71 replication by regulating IRES-dependent translation of viral proteins","volume":"106","author":"Gao","year":"2014","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2018.12.009_bib0575","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejcb.2012.09.001","article-title":"The kinase inhibitor Sorafenib impairs the antiviral effect of interferon alpha on hepatitis C virus replication","volume":"92","author":"Himmelsbach","year":"2013","journal-title":"Eur J Cell Biol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0580","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1002\/jcp.25014","article-title":"GRP78\/Dna K is a target for Nexavar\/Stivarga\/Votrient in the treatment of human malignancies, viral infections and bacterial diseases","volume":"230","author":"Roberts","year":"2015","journal-title":"J Cell Physiol"},{"issue":"2","key":"10.1016\/j.coviro.2018.12.009_bib0585","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/hep.29515","article-title":"Complete response under sorafenib in patients with hepatocellular carcinoma: relationship with dermatologic adverse events","volume":"67","author":"Rimola","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2018.12.009_bib0590","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/annonc\/mdw549","article-title":"Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials","volume":"28","author":"Gyawali","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0595","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1177\/1756283X15618129","article-title":"Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib","volume":"9","author":"Granito","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0600","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/ijc.28544","article-title":"Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials","volume":"135","author":"Santoni","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.coviro.2018.12.009_bib0605","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s12032-012-0345-2","article-title":"Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions","volume":"30","author":"Brunocilla","year":"2013","journal-title":"Med Oncol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0610","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/hep.25639","article-title":"Drug-related adverse events may predict efficacy in sorafenib therapy for hepatocellular carcinoma","volume":"56","author":"Zhao","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2018.12.009_bib0615","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1200\/JCO.2009.27.2757","article-title":"Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials","volume":"28","author":"Choueiri","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0620","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gene.2014.11.051","article-title":"NEDD4-2 (NEDD4L): the ubiquitin ligase for multiple membrane proteins","volume":"557","author":"Goel","year":"2015","journal-title":"Gene"},{"key":"10.1016\/j.coviro.2018.12.009_bib0625","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1128\/JVI.73.4.2921-2929.1999","article-title":"A proline-rich motif within the matrix protein of vesicular stomatitis virus and rabies virus interacts with WW domains of cellular proteins: implications for viral budding","volume":"73","author":"Harty","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0630","doi-asserted-by":"crossref","first-page":"7294","DOI":"10.1128\/JVI.00591-14","article-title":"Small-molecule probes targeting the viral PPxY-host Nedd4 interface block egress of a broad range of RNA viruses","volume":"88","author":"Han","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0635","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1126\/science.1125280","article-title":"Crystal structure of the rabies virus nucleoprotein-RNA complex","volume":"313","author":"Albertini","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.coviro.2018.12.009_bib0640","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s00018-007-7298-1","article-title":"Structural aspects of rabies virus replication","volume":"65","author":"Albertini","year":"2008","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.coviro.2018.12.009_bib0645","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1006\/viro.2001.1271","article-title":"Genetic constraints and the adaptive evolution of rabies virus in nature","volume":"292","author":"Holmes","year":"2002","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2018.12.009_bib0650","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1006\/viro.1995.1285","article-title":"Genetic polymorphism in the rabies virus nucleoprotein gene","volume":"209","author":"Kissi","year":"1995","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2018.12.009_bib0655","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1128\/JVI.76.9.4153-4161.2002","article-title":"Both viral transcription and replication are reduced when the rabies virus nucleoprotein is not phosphorylated","volume":"76","author":"Wu","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0660","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0006-291X(03)00594-1","article-title":"Rabies virus nucleoprotein is phosphorylated by cellular casein kinase II","volume":"304","author":"Wu","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.coviro.2018.12.009_bib0665","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/B978-0-12-387040-7.00016-0","article-title":"Design of future rabies biologics and antiviral drugs","volume":"79","author":"Smith","year":"2011","journal-title":"Adv Virus Res"},{"key":"10.1016\/j.coviro.2018.12.009_bib0670","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1128\/AAC.00211-07","article-title":"RSV604, a novel inhibitor of respiratory syncytial virus replication","volume":"51","author":"Chapman","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2018.12.009_bib0675","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1128\/JVI.01520-09","article-title":"Structure of the nucleoprotein binding domain of Mokola virus phosphoprotein","volume":"84","author":"Assenberg","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0680","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jmb.2004.08.071","article-title":"Structure and function of the C-terminal domain of the polymerase cofactor of rabies virus","volume":"343","author":"Mavrakis","year":"2004","journal-title":"J Mol Biol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0685","doi-asserted-by":"crossref","first-page":"322","DOI":"10.4161\/rna.7.3.11931","article-title":"The structure of the nucleoprotein binding domain of lyssavirus phosphoprotein reveals a structural relationship between the N-RNA binding domains of Rhabdoviridae and Paramyxoviridae","volume":"7","author":"Delmas","year":"2010","journal-title":"RNA Biol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0690","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1128\/JVI.02557-09","article-title":"Structure of the dimerization domain of the rabies virus phosphoprotein","volume":"84","author":"Ivanov","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0695","doi-asserted-by":"crossref","first-page":"7410","DOI":"10.1128\/JVI.78.14.7410-7417.2004","article-title":"Antiviral drug discovery strategy using combinatorial libraries of structurally constrained peptides","volume":"78","author":"Real","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0700","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fchem.2014.00062","article-title":"Current challenges in peptide-based drug discovery","volume":"2","author":"Otvos","year":"2014","journal-title":"Front Chem"},{"key":"10.1016\/j.coviro.2018.12.009_bib0705","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1128\/JVI.73.1.242-250.1999","article-title":"Matrix protein of rabies virus is responsible for the assembly and budding of bullet-shaped particles and interacts with the transmembrane spike glycoprotein G","volume":"73","author":"Mebatsion","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0710","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.yexcr.2016.07.008","article-title":"Rabies virus matrix protein induces apoptosis by targeting mitochondria","volume":"347","author":"Zan","year":"2016","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.coviro.2018.12.009_bib0715","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.virusres.2008.05.011","article-title":"Amino acid at position 95 of the matrix protein is a cytopathic determinant of rabies virus","volume":"137","author":"Mita","year":"2008","journal-title":"Virus Res"},{"key":"10.1016\/j.coviro.2018.12.009_bib0720","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1093\/nar\/gkl1127","article-title":"Rabies virus matrix protein interplay with eIF3, new insights into rabies virus pathogenesis","volume":"35","author":"Komarova","year":"2007","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.coviro.2018.12.009_bib0725","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S1097-2765(00)00120-9","article-title":"Vesicular stomatitis virus matrix protein inhibits host cell gene expression by targeting the nucleoporin Nup98","volume":"6","author":"von Kobbe","year":"2000","journal-title":"Mol Cell"},{"key":"10.1016\/j.coviro.2018.12.009_bib0730","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000251","article-title":"Rhabdovirus matrix protein structures reveal a novel mode of self-association","volume":"4","author":"Graham","year":"2008","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2018.12.009_bib0735","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.bmcl.2012.11.041","article-title":"Discovery of a small-molecule antiviral targeting the HIV-1 matrix protein","volume":"23","author":"Zentner","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.coviro.2018.12.009_bib0740","doi-asserted-by":"crossref","first-page":"9730","DOI":"10.1128\/JVI.00889-08","article-title":"PPEY motif within the rabies virus (RV) matrix protein is essential for efficient virion release and RV pathogenicity","volume":"82","author":"Wirblich","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0745","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1128\/JVI.78.6.2657-2665.2004","article-title":"Budding of PPxY-containing rhabdoviruses is not dependent on host proteins TGS101 and VPS4A","volume":"78","author":"Irie","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0750","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006697","article-title":"Regulation of NF-kappaB by the p105-ABIN2-TPL2 complex and RelAp43 during rabies virus infection","volume":"13","author":"Besson","year":"2017","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2018.12.009_bib0755","doi-asserted-by":"crossref","DOI":"10.1038\/srep39420","article-title":"The matrix protein of rabies virus binds to RelAp43 to modulate NF-kappaB-dependent gene expression related to innate immunity","volume":"6","author":"Ben Khalifa","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.coviro.2018.12.009_bib0760","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.1039\/C8SM00919H","article-title":"Characterisation of protein aggregation with the Smoluchowski coagulation approach for use in biopharmaceuticals","volume":"14","author":"Zidar","year":"2018","journal-title":"Soft Matter"},{"key":"10.1016\/j.coviro.2018.12.009_bib0765","first-page":"129","article-title":"Monoclonal antibody studies of rabies viruses isolated from Thailand","volume":"21","author":"Thongcharoen","year":"1990","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"10.1016\/j.coviro.2018.12.009_bib0770","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/0264-410X(88)90184-3","article-title":"Immunity against the European bat rabies (Duvenhage) virus induced by rabies vaccines: an experimental study in mice","volume":"6","author":"Lafon","year":"1988","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2018.12.009_bib0775","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1099\/vir.0.065953-0","article-title":"Comparative studies on the genetic, antigenic and pathogenic characteristics of Bokeloh bat lyssavirus","volume":"95","author":"Nolden","year":"2014","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0780","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1099\/vir.0.061952-0","article-title":"Antigenic and genetic characterization of a divergent African virus, Ikoma lyssavirus","volume":"95","author":"Horton","year":"2014","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0785","doi-asserted-by":"crossref","first-page":"5897","DOI":"10.1016\/j.vaccine.2013.09.038","article-title":"Alanine scanning of the rabies virus glycoprotein antigenic site III using recombinant rabies virus: implication for post-exposure treatment","volume":"31","author":"Papaneri","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2018.12.009_bib0790","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1128\/jcm.30.9.2419-2426.1992","article-title":"Antigenic and molecular characterization of bat rabies virus in Europe","volume":"30","author":"Bourhy","year":"1992","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.coviro.2018.12.009_sbref0795","article-title":"In vivo efficacy of a cocktail of human monoclonal antibodies (CL184) against diverse North American bat rabies virus variants","volume":"2","author":"Franka","year":"2017","journal-title":"Trop Med Infect Dis"},{"key":"10.1016\/j.coviro.2018.12.009_sbref0800","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006133","article-title":"SYN023, a novel humanized monoclonal antibody cocktail, for post-exposure prophylaxis of rabies","volume":"11","author":"Chao","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.coviro.2018.12.009_bib0805","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/14760584.2017.1294068","article-title":"Development of a new purified vero cell rabies vaccine (Rabivax-S) at the serum institute of India Pvt Ltd","volume":"16","author":"Kulkarni","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.coviro.2018.12.009_bib0810","doi-asserted-by":"crossref","first-page":"407","DOI":"10.15252\/emmm.201505986","article-title":"Development of broad-spectrum human monoclonal antibodies for rabies post-exposure prophylaxis","volume":"8","author":"De Benedictis","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.coviro.2018.12.009_bib0815","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jcis.2012.06.055","article-title":"Colloidal interactions between monoclonal antibodies in aqueous solutions","volume":"384","author":"Arzensek","year":"2012","journal-title":"J Colloid Interface Sci"},{"key":"10.1016\/j.coviro.2018.12.009_bib0820","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1086\/500470","article-title":"Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin","volume":"193","author":"Goudsmit","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2018.12.009_bib0825","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1083\/jcb.150.3.601","article-title":"Rabies virus-induced membrane fusion pathway","volume":"150","author":"Gaudin","year":"2000","journal-title":"J Cell Biol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0830","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1021\/jm5017768","article-title":"Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study","volume":"58","author":"Mackman","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.coviro.2018.12.009_bib0835","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1405198111","article-title":"Cross-resistance mechanism of respiratory syncytial virus against structurally diverse entry inhibitors","volume":"111","author":"Yan","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2018.12.009_bib0840","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1128\/AAC.49.6.2460-2466.2005","article-title":"Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms","volume":"49","author":"Douglas","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2018.12.009_bib0845","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3390\/v4010117","article-title":"Molecular and cellular aspects of rhabdovirus entry","volume":"4","author":"Albertini","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2018.12.009_bib0850","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/infdis\/jix606","article-title":"Combination therapy with neuraminidase and polymerase inhibitors in nude mice infected with influenza virus","volume":"217","author":"Kiso","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2018.12.009_bib0855","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/infdis\/jix605","article-title":"The anti-human immunodeficiency virus drug Tenofovir, a reverse transcriptase inhibitor, also targets the herpes simplex virus DNA polymerase","volume":"217","author":"Andrei","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2018.12.009_bib0860","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.pharmthera.2017.10.009","article-title":"Direct antiviral agents (DAAs) - a new age in the treatment of hepatitis C virus infection","volume":"183","author":"Spengler","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.coviro.2018.12.009_bib0865","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.virusres.2017.01.008","article-title":"Polymerases of paramyxoviruses and pneumoviruses","volume":"234","author":"Fearns","year":"2017","journal-title":"Virus Res"},{"key":"10.1016\/j.coviro.2018.12.009_sbref0870","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3389\/fmicb.2015.00459","article-title":"The paramyxovirus polymerase complex as a target for next-generation anti-paramyxovirus therapeutics","volume":"6","author":"Cox","year":"2015","journal-title":"Front Microbiol"},{"issue":"December","key":"10.1016\/j.coviro.2018.12.009_bib0875","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.antiviral.2018.10.026","article-title":"Favipiravir inhibits in vitro Usutu virus replication and delays disease progression in an infection model in mice","volume":"160","author":"Segura Guerrero","year":"2018","journal-title":"Antiviral Res"},{"issue":"2","key":"10.1016\/j.coviro.2018.12.009_bib0880","first-page":"01217","article-title":"Determining the mutation bias of favipiravir in influenza using next-generation sequencing","volume":"93","author":"Goldhill","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0885","doi-asserted-by":"crossref","DOI":"10.1177\/2040206618807580","article-title":"The effectiveness of antiviral agents with broad-spectrum activity against chikungunya virus varies between host cell lines","volume":"26","author":"Franco","year":"2018","journal-title":"Antivir Chem Chemother"},{"key":"10.1016\/j.coviro.2018.12.009_bib0890","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1811345115","article-title":"The mechanism of resistance to favipiravir in influenza","author":"Goldhill","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2018.12.009_bib0895","doi-asserted-by":"crossref","first-page":"7604","DOI":"10.1038\/s41598-018-25780-3","article-title":"Favipiravir (T-705) protects against Nipah virus infection in the hamster model","volume":"8","author":"Dawes","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.coviro.2018.12.009_bib0900","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/infdis\/jiy153","article-title":"Extending the antiviral value of favipiravir","volume":"218","author":"de la Torre","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2018.12.009_bib0905","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.antiviral.2018.03.003","article-title":"Favipiravir as a potential countermeasure against neglected and emerging RNA viruses","volume":"153","author":"Delang","year":"2018","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2018.12.009_sbref0910","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00766-18","article-title":"Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses","volume":"62","author":"Yoon","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2018.12.009_bib0915","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02395-16","article-title":"Characterization of beta-d-N(4)-hydroxycytidine as a novel inhibitor of Chikungunya virus","volume":"61","author":"Ehteshami","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2018.12.009_bib0920","doi-asserted-by":"crossref","first-page":"6233","DOI":"10.3390\/v7122934","article-title":"Identification of a new ribonucleoside inhibitor of ebola virus replication","volume":"7","author":"Reynard","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2018.12.009_bib0925","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1128\/AAC.01176-09","article-title":"Cellular pharmacology of the anti-hepatitis B virus agent beta-L-2\u2032,3\u2032-didehydro-2\u2032,3\u2032-dideoxy-N4-hydroxycytidine: relevance for activation in HepG2 cells","volume":"54","author":"Matthes","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2018.12.009_bib0930","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/095632020601700505","article-title":"Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB\/c mice","volume":"17","author":"Barnard","year":"2006","journal-title":"Antivir Chem Chemother"},{"key":"10.1016\/j.coviro.2018.12.009_bib0935","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1081\/NCN-200059224","article-title":"Synthesis and in vitro anti-HCV activity of beta-D- and 1-2\u2032-deoxy-2\u2032-fluororibonucleosides","volume":"24","author":"Shi","year":"2005","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.coviro.2018.12.009_bib0940","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/095632020401500105","article-title":"Synthesis of beta-enantiomers of N4-hydroxy-3\u2032-deoxypyrimidine nucleosides and their evaluation against bovine viral diarrhoea virus and hepatitis C virus in cell culture","volume":"15","author":"Hollecker","year":"2004","journal-title":"Antivir Chem Chemother"},{"key":"10.1016\/j.coviro.2018.12.009_bib0945","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/df98339d-6bdb-40ed-af83-cc38b249264a","article-title":"Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans","volume":"3","author":"Muller","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.coviro.2018.12.009_bib0950","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1099\/vir.0.007765-0","article-title":"Evolutionary history and dynamics of dog rabies virus in western and central Africa","volume":"90","author":"Talbi","year":"2009","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2018.12.009_bib0955","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0264-410X(98)00196-0","article-title":"Studies on the structures and antigenic properties of rabies virus glycoprotein analogues produced in yeast cells","volume":"17","author":"Sakamoto","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2018.12.009_bib0960","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0168-1702(92)90095-Q","article-title":"Characterization of rabies virus glycoprotein expressed by recombinant baculovirus","volume":"25","author":"Tuchiya","year":"1992","journal-title":"Virus Res"},{"key":"10.1016\/j.coviro.2018.12.009_bib0965","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1007\/s00018-008-7534-3","article-title":"Structures of vesicular stomatitis virus glycoprotein: membrane fusion revisited","volume":"65","author":"Roche","year":"2008","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.coviro.2018.12.009_bib0970","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/13550280600902295","article-title":"Failure of therapeutic coma and ketamine for therapy of human rabies","volume":"12","author":"Hemachudha","year":"2006","journal-title":"J Neurovirol"},{"key":"10.1016\/j.coviro.2018.12.009_sbref0975","article-title":"Re-evaluating the effect of Favipiravir treatment on rabies virus infection","author":"Banyard","year":"2017","journal-title":"Vaccine"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625718301743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625718301743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:01:36Z","timestamp":1761818496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625718301743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":195,"alternative-id":["S1879625718301743"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2018.12.009","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Status of antiviral therapeutics against rabies virus and related emerging lyssaviruses","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2018.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}